AI assistant
AbbVie Inc. — Director's Dealing 2022
May 20, 2022
29755_dirs_2022-05-20_3558735c-997e-4daf-ad80-ca3700a08042.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-03-01
Reporting Person: Gosebruch Henry O (EVP, Chief Strategy Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-01 | Common Stock, $0.01 par value | S | 15733 | $146.8105 | Disposed | 62767 | Indirect |
| 2022-03-01 | Common Stock, $0.01 par value | S | 5167 | $147.6015 | Disposed | 57600 | Indirect |
| 2022-03-01 | Common Stock, $0.01 par value | S | 4000 | $148.706 | Disposed | 53600 | Indirect |
| 2022-03-01 | Common Stock, $0.01 par value | S | 100 | $149.381 | Disposed | 53500 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.01 par value | 41623 | Direct |
| Common Stock, $0.01 par value | 3457 | Indirect |
Footnotes
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F6: Balance in AbbVie Savings program as of January 31, 2022.
F7: Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error.